Trials / Completed
CompletedNCT02731729
Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy
A Randomized, Phase 2 Study of Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Parker Institute for Cancer Immunotherapy · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to learn whether patients whose disease grows after being treated with nivolumab or pembrolizumab respond to ipilimumab (Yervoy®) alone or in combination with nivolumab (Opdivo®).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ipilimumab | |
| DRUG | nivolumab |
Timeline
- Start date
- 2016-06-21
- Primary completion
- 2018-08-27
- Completion
- 2019-02-13
- First posted
- 2016-04-07
- Last updated
- 2022-12-23
- Results posted
- 2021-02-21
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02731729. Inclusion in this directory is not an endorsement.